A Look at the BioMarin Pipeline for Rare Disease Drugs: Mechanisms, Timelines, and Trade-offs
The BioMarin pipeline for rare disease drugs is a portfolio of roughly a dozen clinical and near-market programs built on four technology platforms: enzyme replacement for lysosomal storage disorders, antisense oligonucleotides for central…
Let's find out